Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines

Figures & data

Table 1. Comparison of baseline data between the two groups.

Item	Control group	Treatment group	p
N (cases)	65	65	–
M (cases)	17	8	0.44
F (cases)	48	57
Age (years)	40.32 ± 14.192	42.92 ± 13.467	0.81
FT3 (pmol/l)	14.90 (20.91)	11.88 (17.12)	>0.05
FT4 (pmol/l)	38.08 (53.37)	34.98 (51.89)	>0.05
TSH (mIU/L)	0.005 (0.004)	0.005 (0.0035)	>0.05
TGAb (IU/ML)	87.35 (261.44)	246.7 (493.76)	>0.05
TPOAb (IU/ML)	103.0 (310.0)	129.4 (316.67)	>0.05
TRAb (mIU/ML)	8.83 (20.1)	8.48 (20.06)	>0.05
Symptom score	33.51 ± 7.115	37.06 ± 6.619	>0.05
CD4^+/CD25^+ (%)	9.3 (4.95)	6.7 (5.45)	>0.05
IL-10 (pg/ml)	5.0 (0)	5.0 (0.6)	>0.05
IL-6 (pg/ml)	2.2 (1.2)	2.0 (0.6)	>0.05
TNF-α (pg/ml)	6.8 (6.1)	8.76 (7.15)	>0.05
IFN-γ (pg/ml)	7.0 (4.95)	6.3 (5.45)	>0.05

Table 2. Comparison of thyroid functions and antibodies before and after the treatment.

	Control group			Treatment group
Item	Before	6-week after	12-week after	Before	6-week after	12-week after
FT3 (pmol/l)	17.59 ± 12.15	9.54 ± 6.99**	8.11 ± 6.0**^▴▴	16.85 ± 13.08	8.85 ± 6.27**	6.98 ± 4.45**^▴▴
FT4 (pmol/l)	46.21 ± 28.54	25.88 ± 17.53**	22.74 ± 16.18**^▴▴	46.50 ± 30.46	26.90 ± 16.73**	20.71 ± 10.61**^▴▴
TSH (mIU/L)	0.86 ± 5.83	1.79 ± 7.67	1.76 ± 5.31	0.77 ± 3.65	1.15 ± 2.75	1.79 ± 5.47*
TGAb (IU/ML)	276.76 ± 579.16	288.43 ± 541.47	243.74 ± 468.38	473.10 ± 763.72	443.70 ± 759.33	453.51 ± 863.43
TPOAb (IU/ML)	192.24 ± 198.43	188.53 ± 199.17	194.45 ± 199.44	196.18 ± 191.98	201.65 ± 231.73	169.20 ± 178.16
TRAb (mIU/ML)	23.12 ± 73.73	13.73 ± 12.24	11.48 ± 11.78^▴	13.53 ± 12.76	11.89 ± 12.26	9.15 ± 10.82**^▴▴

Intragroup comparison with that before the treatment *p < 0.05, **p < 0.001, intragroup comparison with that 6-week after treatment ^▴p < 0.05, ^▴▴p < 0.001, and no significant difference was detected between groups at the same time points.

Table 3. Comparison of CD4⁺ CD25⁺, IL-6 and 10, TNF-α, and IFN-γ between the two groups before and 12 weeks after the treatment (M (QR)).

	CD4^+/CD25^+		IL-10		IL-6		TNF-α		IFN-γ
Groups	Before	After	Before	After	Before	After	Before	After	Before	After
Control	9.3 (4.95)	9.1 (4.6)	5.0 (0.0)	5.0 (0.0)	2.2 (1.2)	2.0 (0.4)*	6.8 (6.1)	4.4 (5.88)**	7.0 (4.95)	6.0 (4.55)*
Treatment	6.7 (5.45)	8.1 (4.45)*	5.0 (0.6)	5.0 (0)*	2.2 (0.6)	2.0 (0.3)	8.76 (7.15)	5.5 (5.8)*	6.3 (5.45)	6.9 (6.4)

Compared with that before the treatment *p < 0.05, **p < 0.01, and no significant difference was detected between groups at the same time points.

Table 4. Comparison of total score of TCM syndromes at different time points between the two groups (x ± s).

Group	Before	6-week after	12-week after
Control	33.71 ± 6.789	26.26 ± 6.109**	21.29 ± 6.578**^▴▴
Treatment	35.00 ± 6.745	25.46 ± 5.596**	18.22 ± 6.496**^▴▴

Intragroup comparison with that before the treatment *p < 0.05, **p < 0.001, intragroup comparison with that 6-week after the treatment ^▴p < 0.05, ^▴▴p < 0.001, and no significant difference was detected between groups at the same time points.

Table 5. Comparison of total efficiencies in improving goitre, shortness of breath, and thirst between the two groups.

	Goitre		Fatigue and acratia		Breath shortness		Dry mouth and thirst
Group	Ineffective	effective	Ineffective	effective	Ineffective	effective	Ineffective	effective
Control	56	9	11	54	17	48	23	42
Treatment	37	28^▴	4	61	8	56	11	54^▴

Compared with the treatment group, ^▴p < 0.05.

Table 6. Efficacies of main TCM syndromes in the two groups.

Group	n	Cure	Significantly effective	Effective	Ineffective	Total effective rate (%)
Control	65	0	6	28	31	52.3
Treatment	65	0	5	52	8	87.7^▴

Compared with the control group ^▴p < 0.05.